These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 1588269)
1. Effect of reduction of plasma triglycerides with gemfibrozil on high-density-lipoprotein-cholesterol concentrations. Rubins HB; Robins SJ J Intern Med; 1992 Apr; 231(4):421-6. PubMed ID: 1588269 [TBL] [Abstract][Full Text] [Related]
2. Gemfibrozil treatment of the high triglyceride-low high-density lipoprotein cholesterol trait in men with established atherosclerosis. Knipscheer HC; Nurmohamed MT; Van den Ende A; Plaat B; Pruijs HJ; Mulder WJ; Kastelein JJ J Intern Med; 1994 Oct; 236(4):377-84. PubMed ID: 7931040 [TBL] [Abstract][Full Text] [Related]
3. Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels. Schaefer EJ; Lamon-Fava S; Cole T; Sprecher DL; Cilla DD; Balagtas CC; Rowan JP; Black DM Atherosclerosis; 1996 Nov; 127(1):113-22. PubMed ID: 9006811 [TBL] [Abstract][Full Text] [Related]
4. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group. Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751 [TBL] [Abstract][Full Text] [Related]
5. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD Arch Intern Med; 2000 Apr; 160(8):1177-84. PubMed ID: 10789612 [TBL] [Abstract][Full Text] [Related]
6. The efficacy of gemfibrozil therapy for raising high density lipoprotein levels. Weis S; Kudchodkar BJ; Clearfield MB; Lacko AG Artery; 1992; 19(6):353-66. PubMed ID: 1471924 [TBL] [Abstract][Full Text] [Related]
7. Low high-density lipoprotein cholesterol and other coronary heart disease risk factors in patients with total cholesterol levels greater than 5.17 mmol/L (200 mg/dL) in family practice. A report from CEN. J Am Board Fam Pract; 1991; 4(5):285-97. PubMed ID: 1746296 [TBL] [Abstract][Full Text] [Related]
12. Effect of gemfibrozil on the concentration and composition of very low density and low density lipoprotein subfractions in hypertriglyceridemic patients. Dachet C; Cavallero E; Martin C; Girardot G; Jacotot B Atherosclerosis; 1995 Feb; 113(1):1-9. PubMed ID: 7755644 [TBL] [Abstract][Full Text] [Related]
13. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. Rubins HB; Robins SJ; Iwane MK; Boden WE; Elam MB; Fye CL; Gordon DJ; Schaefer EJ; Schectman G; Wittes JT Am J Cardiol; 1993 Jan; 71(1):45-52. PubMed ID: 8420235 [TBL] [Abstract][Full Text] [Related]
14. Effect of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol: a randomized, double-blind, placebo-controlled, crossover study. Miller M; Bachorik PS; McCrindle BW; Kwiterovich PO Am J Med; 1993 Jan; 94(1):7-12. PubMed ID: 8420303 [TBL] [Abstract][Full Text] [Related]
15. Fibrinolytic response in subjects with hypertriglyceridemia and low HDL cholesterol. Cimminiello C; Vigorelli P; Piliego T; Soncini M; Toschi V; Arpaia G; Perolini S; Bonfardeci C Biomed Pharmacother; 1997; 51(4):164-9. PubMed ID: 9207984 [TBL] [Abstract][Full Text] [Related]
16. Effect of gemfibrozil and lovastatin on postprandial lipoprotein clearance in the hypoalphalipoproteinemia and hypertriglyceridemia syndrome. Simo IE; Yakichuk JA; Ooi TC Atherosclerosis; 1993 Apr; 100(1):55-64. PubMed ID: 8318063 [TBL] [Abstract][Full Text] [Related]
17. Changes of lipoprotein profile in familial dysbetalipoproteinemia with gemfibrozil. Zhao SP; Smelt AH; Leuven JA; Vroom TF; van der Laarse A; van 't Hooft FM Am J Med; 1994 Jan; 96(1):49-56. PubMed ID: 8304363 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia. King JM; Crouse JR; Terry JG; Morgan TM; Spray BJ; Miller NE Am J Med; 1994 Oct; 97(4):323-31. PubMed ID: 7942933 [TBL] [Abstract][Full Text] [Related]
19. The effect of gemfibrozil on lipid profile and glucose metabolism in hypertriglyceridaemic well-controlled non-insulin-dependent diabetic patients. For the Gemfibrozil Study Group. Avogaro A; Piliego T; Catapano A; Miola M; Tiengo A Acta Diabetol; 1999 Jun; 36(1-2):27-33. PubMed ID: 10436249 [TBL] [Abstract][Full Text] [Related]
20. Lipoprotein lipids in older people. Results from the Cardiovascular Health Study. The CHS Collaborative Research Group. Ettinger WH; Wahl PW; Kuller LH; Bush TL; Tracy RP; Manolio TA; Borhani NO; Wong ND; O'Leary DH Circulation; 1992 Sep; 86(3):858-69. PubMed ID: 1516198 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]